Ω-3 Fatty Acids for the Prevention of Atrial Fibrillation After Coronary Artery Bypass Surgery: A Randomized, Controlled Trial.
The aim of this study was to assess the efficacy of preoperative and postoperative treatment with ω-3 polyunsaturated fatty acids (PUFAs) in preventing the occurrence of atrial fibrillation (AF) after coronary artery bypass graft surgery (CABG). Postoperative AF is a common complication of CABG. There is growing clinical evidence that PUFAs have cardiac antiarrhythmic effects. A total of 160 patients were prospectively randomized to a control group (81 patients, 13 female, 64.9 ± 9.1 years) or PUFAs 2 g/day (79 patients, 11 female, 66.2 ± 8.0 years) for at least 5 days before elective CABG and until the day of discharge from the hospital. The primary end point was the development of AF in the postoperative period. The secondary end point was the hospital length of stay after surgery. All end points were independently adjudicated by 2 cardiologists blinded to treatment assignment. The clinical and surgical characteristics of the patients in the 2 groups were similar. Postoperative AF developed in 27 patients of the control group (33.3%) and in 12 patients of the PUFAs group (15.2%) ( p = .013). There was no significant difference in the incidence of nonfatal postoperative complications, and postoperative mortality was similar in the PUFAs-treated patients (1.3%) vs controls (2.5%). After CABG, the PUFAs patients were hospitalized for significantly fewer days than controls (7.3 ± 2.1 days vs 8.2 ± 2.6 days, p = .017). This study first demonstrates that PUFA administration during hospitalization in patients undergoing CABG substantially reduced the incidence of postoperative AF (54.4%) and was associated with a shorter hospital stay. ( J Am Coll Cardiol. 2005;45:1723-1728.).